Analysts predict that CymaBay Therapeutics Inc (NASDAQ:CBAY) will announce earnings per share (EPS) of ($0.36) for the current quarter, according to Zacks. Zero analysts have made estimates for CymaBay Therapeutics’ earnings, with estimates ranging from ($0.41) to ($0.34). CymaBay Therapeutics posted earnings per share of ($0.30) in the same quarter last year, which would indicate a negative year-over-year growth rate of 20%. The firm is scheduled to announce its next quarterly earnings report on Thursday, August 8th.

According to Zacks, analysts expect that CymaBay Therapeutics will report full year earnings of ($1.48) per share for the current year, with EPS estimates ranging from ($1.74) to ($1.36). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.58) per share, with EPS estimates ranging from ($2.05) to ($0.91). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow CymaBay Therapeutics.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03).

A number of research analysts recently weighed in on CBAY shares. Oppenheimer set a $18.00 price target on shares of CymaBay Therapeutics and gave the company a “buy” rating in a research report on Sunday, April 14th. BidaskClub raised shares of CymaBay Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, April 30th. Piper Jaffray Companies set a $30.00 price target on shares of CymaBay Therapeutics and gave the company a “buy” rating in a research report on Wednesday, February 20th. ValuEngine lowered shares of CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. Finally, Zacks Investment Research raised shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. CymaBay Therapeutics has an average rating of “Buy” and a consensus price target of $14.44.

Shares of NASDAQ CBAY traded up $0.36 during mid-day trading on Monday, reaching $6.64. 51,385 shares of the company’s stock traded hands, compared to its average volume of 2,364,417. The company has a market capitalization of $431.40 million, a PE ratio of -5.29 and a beta of 1.73. The business has a 50-day moving average of $12.03. CymaBay Therapeutics has a 1-year low of $4.82 and a 1-year high of $15.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.66 and a current ratio of 18.66.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace North America L.P. lifted its stake in CymaBay Therapeutics by 1,744.6% during the 1st quarter. Marshall Wace North America L.P. now owns 122,792 shares of the biopharmaceutical company’s stock valued at $1,631,000 after acquiring an additional 116,135 shares during the period. Marshall Wace LLP lifted its stake in CymaBay Therapeutics by 17.0% during the 1st quarter. Marshall Wace LLP now owns 63,589 shares of the biopharmaceutical company’s stock valued at $844,000 after acquiring an additional 9,231 shares during the period. Vivo Capital LLC lifted its stake in CymaBay Therapeutics by 126.9% during the 1st quarter. Vivo Capital LLC now owns 2,056,000 shares of the biopharmaceutical company’s stock valued at $27,304,000 after acquiring an additional 1,150,000 shares during the period. Spark Investment Management LLC lifted its stake in CymaBay Therapeutics by 47.9% during the 1st quarter. Spark Investment Management LLC now owns 183,800 shares of the biopharmaceutical company’s stock valued at $2,440,000 after acquiring an additional 59,500 shares during the period. Finally, Eagle Asset Management Inc. lifted its stake in CymaBay Therapeutics by 5.6% during the 1st quarter. Eagle Asset Management Inc. now owns 3,011,623 shares of the biopharmaceutical company’s stock valued at $39,994,000 after acquiring an additional 158,650 shares during the period. 99.53% of the stock is currently owned by institutional investors.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Read More: Understanding Analyst Ratings

Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.